I. COMMENCED TRADING IN October | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
INITIAL OFFERINGS | ||||||||
Pacific Biosciences Inc. (PACB)1 |
8/16 |
10/27 |
12.5S |
$16 |
50. 1 |
J.P. Morgan Securities |
$200 |
$801.6 |
|
Total: $200M Number of IPOs in October: 1 | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
FOLLOW-ON OFFERINGS | ||||||||
Aegerion Pharmaceuticals Inc. (AEGR)2 |
8/10 |
10/25 |
5S |
$9.50 |
16.9 |
Leerink Swann |
$47.5 |
$160.55 |
Anadys Pharmaceuticals Inc. (ANDS)3 |
4/23/09 |
10/15 |
13.9S |
$1 .80 |
57.1 |
Lazard Capital Markets |
$25 |
$102.78 |
Ariad Pharmaceuticals Inc. (ARIA)4 |
1/21 |
10/25 |
16S |
$3.70 |
126.9 |
Jefferies & Co. Inc. |
$59.2 |
$469.53 |
Celgene Corp. (CELG)5 |
10/4 |
10/5 |
Notes |
N/A |
N/A |
Citigroup Global Markets |
$1.25B |
N/A |
Chelsea Therapeutics International Inc. (CHTP)6 |
9/30 |
10/4 |
8.21S |
$4.90 |
49.07 |
Deutsche Bank Sec. |
$40.23 |
$240.4 |
Cubist Pharmaceuticals Inc. (CBST)7 |
10/19 |
10/19 |
Convertible notes |
NA |
N/A |
Goldman Sachs & Co. |
$450 |
N/A |
Cytori Therapeutics Inc. (CYTX)8 |
2/11/09 |
10/8 |
4.6S |
$4.50 |
50.5 |
Jefferies & Co. Inc. |
$20.7 |
$227.25 |
Dynavax Technologies Corp. (DVAX)9 |
10/6 |
10/28 |
26.45S |
$1.70 |
114.75 |
Jefferies & Co. |
$44.97 |
$195.1 |
GTx Inc. (GTXI)10 |
1/17/08 |
10/27 |
14.3S |
$2.80 |
50.7 |
Lazard Capital Markets |
$40 |
$141.96 |
OncoGenex Pharmaceuticals Inc. (OGXI) |
7/17/09 |
10/19 |
3.2U |
$15.75 |
9.7 |
Stifel Nicolaus Weisel |
$50 |
$152.8 |
Regeneron Pharmaceuticals Inc. (REGN)11 |
10/6 |
10/8 |
6.325S |
$27.69 |
86.33 |
Citibank Global Markets |
$175.14 |
$2,390.5 |
Sunesis Pharmaceuticals Inc. (SNSS) |
5/20 |
10/4 |
44.1U |
$0.35 |
265.3 |
Cowen and Co. LLC |
$15.5 |
$92.9 |
|
Total: $2,218.24M Number of follow-on offerings in October: 12 | ||||||||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. 1 Pacific BioSciences' overallotment option: 1.875M shares. 2 Aegerion's overallotment option: 750,000 shares. 3 Anadys' overallotment option: 2. 1M shares. 4 Ariad's overallotment option: 2.4M shares. 5 Celgene priced $500M in 2.45% senior notes due October 2015, $500M in 3.95% senior notes due October 2020 and $250M in 5.7% senior notes due October 2040. 6 Includes Chelsea's overallotment option: 1 .07M shares. 7 Includes Cubist's overallotment option: $50M in convertible notes. 8 Includes Cytori's overallotment option: 600,000 shares. 9 Includes Dynavax's overallotment option: 3.45M shares. 10 GTX's overallotment option: 2. 1M shares. 11 Includes Regeneron's overallotment option: 825,000 shares. | ||||||||
| II. FILED AND PENDING | ||||||||
| Company (Symbol)# | Date Filed | Shares/Units (M) | Price | Shares Out | Lead, Other Underwriters (M)@ | Gross (US$M) | ||
| INITIAL OFFERINGS | ||||||||
| Aegerion Pharmaceuticals Inc. (AEGR) | 8/10/10 | 5S | $9.50 | N/A | Leerink Swann | $86.25 | ||
| Aldagen Inc. (ALDH) | 10/29/09 | Units | N/A | N/A | Boenning & Scattergood | $46 | ||
| Anacor Pharmaceuticals Inc. (ANAC) | 9/10/10 | N/A | N/A | N/A | Citibank | $86.25 | ||
| BG Medicine Inc. (BGMD) | 1/29/10 | N/A | N/A | N/A | Jefferies & Co. | $86.25 | ||
| BioLineRx Ltd. (BLRX) | 9/24/10 | N/A | N/A | N/A | JMP Securities | $40.25 | ||
| Broadvector Ltd. (Australia; ASX) | 9/8/10 | 42.5S | 20 cents | N/A | N/A | $8.5 | ||
| Complete Genomics Inc. (GNOM) | 7/30/10 | N/A | N/A | N/A | UBS Investment Bank | $86.25 | ||
| Endocyte Inc. (ECYT) | 8/17/10 | N/A | N/A | N/A | RBC Capital Markets | $86.25 | ||
| Horizon Pharma Inc. (HZNP) | 8/3/10 | N/A | N/A | N/A | Jefferies & Co. | $86.25 | ||
| Ikaria Inc. (IKAR) | 5/13/10 | N/A | N/A | N/A | Goldman Sachs | $200 | ||
| Med BioGene Inc. (Canada; MGBI)1 | 12/28/09 | N/A | N/A | N/A | Rodman & Renshaw LLC | $24 | ||
| Prometheus Laboratories Inc. or Prometheus RxDx Corp. (RXDX) | 12/19/07 | N/A | N/A | N/A | Goldman Sachs & Co. | $151.3 | ||
| Quark Pharmaceuticals Inc. (TASE)2 | 9/28/10 | N/A | N/A | N/A | N/A | $20 | ||
| Zogenix Inc. (ZGNX) | 9/8/10 | N/A | N/A | N/A | Wells Fargo Securities LLC | $90 | ||
| Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. CDNX = Canadian Venture Exchange. General shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. 1 Med BioGene secured Rodman & Renshaw for an IPO in the U.S. | ||||||||